title: Intrarenal detection of nitric oxide using electron spin resonance spectroscopy in hypertensive lipopolysaccharide-treated rats.
abstract: The inhibition of nitric oxide (NO) synthesis by chronic administration of NG-nitro-l-arginine methyl ester (l-NAME) in rats is responsible for systemic hypertension. However, the mechanisms involved in this hypertension remain unclear. The effects of chronic l-NAME on kidney and blood NO production were studied in rats in a state of endotoxic shock due to lipopolysaccharide (LPS). A nitric oxide spin trapping technique using electron spin resonance (ESR) spectroscopy has been used to identify and measure the production of NO in the kidney. This method is based on the trapping of nitric oxide by a metal-chelator complex consisting of N-methyl-d-glucamine dithiocarbamate (MGD) and reduced iron (Fe2+) forming a water-soluble NO-FeMGD complex detected by ESR. After LPS injection (14 mg/kg, IV, 6 h before the sacrifice) to rats pretreated with l-NAME (10 mg/kg/d over 14 days), the NO-FeMGD complex was evaluated in the kidney (arbitrary units [AU]/g of kidney) and the density of polynuclear neutrophils was counted by light microscopy. Chronic inhibition of NO synthase by l-NAME, a nonspecific inhibitor, was responsible for a decrease of the NO-FeMGD complex levels in the kidney (24.9 +/- 1.6 AU versus 13.8 +/- 1.3 AU). LPS administration was responsible for a large increase in both NO-FeMGD complex and neutrophil levels in the kidney of normotensive rats (332.6 +/- 12.8 AU versus 24.9 +/- 1.6 AU for NO-FeMGD complex and 1.36 +/- 0.41 versus 0.11 +/- 0.03 for neutrophils). Conversely, LPS administration in hypertensive, l-NAME-pretreated rats was linked to a smaller increase in the NO-FeMGD complex (85.1 +/- 7.9 AU versus 332.6 +/- 12.8 AU) and a larger increase in glomerular neutrophils (2.48 +/- 0.36 versus 1.36 +/- 0.41) compared with normotensive rats. These results are in agreement with a direct implication of NO during LPS-and l-NAME-induced kidney injuries.
authors.affiliation: Laboratoire de Physiopathologie et Pharmacologie Cardiovasculaires Expérimentales, Facultés de Médecine et Pharmacie, Dijon, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Lecour
authors.forename: Dominique
authors.initials: D
authors.lastname: Chevet
authors.forename: Véronique
authors.initials: V
authors.lastname: Maupoil
authors.forename: Maryvonne
authors.initials: M
authors.lastname: Moisant
authors.forename: Colette
authors.initials: C
authors.lastname: Bernard
authors.forename: Jean Pierre
authors.initials: JP
authors.lastname: Zahnd
authors.forename: Guy
authors.initials: G
authors.lastname: Touchard
authors.forename: François
authors.initials: F
authors.lastname: Briot
authors.forename: Luc
authors.initials: L
authors.lastname: Rochette
mesh_terms: D000818:Animals; D004578:Electron Spin Resonance Spectroscopy / Q000379:methods; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D007668:Kidney / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D018805:Sepsis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology
chemical_list: D008070:Lipopolysaccharides; D009569:Nitric Oxide; D019331:NG-Nitroarginine Methyl Ester